KR20190013846A - 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 - Google Patents

비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20190013846A
KR20190013846A KR1020187036656A KR20187036656A KR20190013846A KR 20190013846 A KR20190013846 A KR 20190013846A KR 1020187036656 A KR1020187036656 A KR 1020187036656A KR 20187036656 A KR20187036656 A KR 20187036656A KR 20190013846 A KR20190013846 A KR 20190013846A
Authority
KR
South Korea
Prior art keywords
compound
weeks
subject
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187036656A
Other languages
English (en)
Korean (ko)
Inventor
레미 루트링거
마이클 데이비슨
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Priority to KR1020237043697A priority Critical patent/KR20240005110A/ko
Publication of KR20190013846A publication Critical patent/KR20190013846A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187036656A 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 Ceased KR20190013846A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043697A KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341590P 2016-05-25 2016-05-25
US62/341,590 2016-05-25
PCT/US2017/034030 WO2017205393A1 (en) 2016-05-25 2017-05-23 Compositions and methods for treating negative symptoms in non-schizophrenic patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043697A Division KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20190013846A true KR20190013846A (ko) 2019-02-11

Family

ID=58794265

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187036656A Ceased KR20190013846A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
KR1020237043697A Ceased KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043697A Ceased KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (2) US20190216793A1 (enExample)
EP (1) EP3463356A1 (enExample)
JP (3) JP2019516756A (enExample)
KR (2) KR20190013846A (enExample)
CN (3) CN113694065A (enExample)
PH (1) PH12018502445A1 (enExample)
SG (2) SG11201810358YA (enExample)
TW (2) TWI820001B (enExample)
WO (1) WO2017205393A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210119803A (ko) * 2020-03-25 2021-10-06 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968977A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) * 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI879755B (zh) * 2020-02-20 2025-04-11 日商田邊三菱製藥股份有限公司 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
IL304920A (en) * 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
WO2024138073A1 (en) * 2022-12-21 2024-06-27 Woebot Labs, Inc. Administering a digital therapeutic using a device interface to treat anxiety or depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1260512E (pt) * 2000-02-29 2007-10-10 Mitsubishi Pharma Corp ''novos derivados de amida cíclicos''
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP2009525979A (ja) * 2006-02-07 2009-07-16 田辺三菱製薬株式会社 ４−アシルアミノピリジン誘導体を介した神経新生
JP2008273954A (ja) * 2007-03-30 2008-11-13 Mitsubishi Tanabe Pharma Corp うつ病の予防及び／又は治療剤
EP3335731B1 (en) * 2010-07-20 2024-09-04 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
EP4070794A3 (en) * 2010-07-20 2023-01-18 Minerva Neurosciences, Inc. Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP3144308B1 (en) * 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
CA2968977A1 (en) * 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210119803A (ko) * 2020-03-25 2021-10-06 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치

Also Published As

Publication number Publication date
JP2022188185A (ja) 2022-12-20
KR20240005110A (ko) 2024-01-11
TW202335672A (zh) 2023-09-16
CN113694065A (zh) 2021-11-26
JP2025000921A (ja) 2025-01-07
TWI820001B (zh) 2023-11-01
US20190216793A1 (en) 2019-07-18
PH12018502445A1 (en) 2019-09-09
SG11201810358YA (en) 2018-12-28
TWI851224B (zh) 2024-08-01
US20230190726A1 (en) 2023-06-22
CN113908156A (zh) 2022-01-11
SG10202011470UA (en) 2021-01-28
WO2017205393A1 (en) 2017-11-30
TW201808288A (zh) 2018-03-16
JP2019516756A (ja) 2019-06-20
CN109689055A (zh) 2019-04-26
EP3463356A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
KR20190013846A (ko) 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
US20240115550A1 (en) Treatment of mental disorders
US20240108602A1 (en) Treatment of mental disorders
WO2024160391A1 (en) Treatment of mental disorders
CN120712084A (zh) 用于治疗母乳喂养母亲的精神障碍的5-甲氧基-n,n-二甲基色胺
US20180244623A1 (en) N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
WO2022241315A1 (en) Reducing side effects of nmda receptor antagonists
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
CN117377470A (zh) 美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
WO2025068714A1 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
CN120641095A (zh) 精神障碍的治疗
KR20250005172A (ko) 정신 장애의 치료
Zornig the beauty of~ relief.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301